• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

    3/12/24 5:36:05 AM ET
    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Parts:O.E.M.
    Consumer Discretionary
    Get the next $ACAD alert in real time by email

    U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday.

    Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) fell sharply in today’s pre-market trading after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.

    ACADIA Pharmaceuticals shares dipped 17.4% to $19.93 in pre-market trading.

    Here are some big stocks recording losses in today’s pre-market trading session.

    • Power & Digital Infrastructure Acquisition II Corp. (NASDAQ:XPDB) shares tumbled 12.6% to $25.57 in pre-market trading after surging 181% on Monday.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 5.9% to $9.16 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.
    • Aeva Technologies, Inc. (NASDAQ:AEVA) shares declined 5.4% to $1.23 in pre-market trading. Aeva said it expects a 1-for-5 reverse stock split of its outstanding shares of common stock will be effective as of March 18, 2024.
    • PLDT Inc. (NYSE:PHI) fell 3.8% to $25.95 in pre-market trading after jumping over 16% on Monday.
    • NextNav Inc. (NASDAQ:NN) declined 3.6% to $5.07 in pre-market trading. NextNav shares jumped 35% on Monday after the company announced it signed an agreement to acquire spectrum licenses covering an additional 4 MHz in the lower 900 MHz band.
    • Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares fell 3.2% to $2.72 in pre-market trading. Lexicon shares surged over 29% on Monday after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.
    • Asana, Inc. (NYSE:ASAN) shares fell 2.4% to $18.35 in pre-market trading following fourth-quarter results.

     

    Now Read This: Top 5 Risk Off Stocks That May Plunge This Quarter

    Don’t forget to check out our premarket coverage here

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $AEVA
    $ASAN
    $LXRX

    CompanyDatePrice TargetRatingAnalyst
    Asana Inc.
    $ASAN
    4/14/2026$7.00Overweight → Neutral
    Piper Sandler
    Asana Inc.
    $ASAN
    4/1/2026$7.00Underperform → Sector Perform
    RBC Capital Mkts
    ACADIA Pharmaceuticals Inc.
    $ACAD
    3/25/2026$29.00Neutral → Buy
    BofA Securities
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    Asana Inc.
    $ASAN
    1/15/2026$16.00Neutral → Buy
    Citigroup
    Asana Inc.
    $ASAN
    12/17/2025Neutral
    BTIG Research
    Asana Inc.
    $ASAN
    12/15/2025$18.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dugel Pravin

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    4/13/26 5:15:06 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Panlilio Alfredo Santos

    4 - PLDT Inc. (0000078150) (Issuer)

    4/13/26 7:47:07 AM ET
    $PHI
    Telecommunications Equipment
    Telecommunications

    SEC Form 4 filed by Schneyer Mark C.

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    4/7/26 7:57:16 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    SEC Filings

    View All

    SEC Form DEFA14A filed by NextNav Inc.

    DEFA14A - NEXTNAV INC. (0001865631) (Filer)

    4/8/26 4:33:45 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    SEC Form DEF 14A filed by NextNav Inc.

    DEF 14A - NEXTNAV INC. (0001865631) (Filer)

    4/8/26 4:32:07 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    SEC Form 6-K filed by PLDT Inc. Sponsored ADR

    6-K - PLDT Inc. (0000078150) (Filer)

    4/1/26 7:09:16 AM ET
    $PHI
    Telecommunications Equipment
    Telecommunications

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to six newly hired non-executive employees and to Mr. Jerome M. Gangitano, the Company's new SVP, CMC Technical Operations. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted to the six newly hired non-executive employees effective as of A

    4/14/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

    New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks and 46 weeks to ≥30 and ≥75 uM increases from Week 8 In all AXPAXLI subjects who had a vitreous floater AE, drug particles are no longer visible (mean time of 20 weeks) Subjects treated with AXPAXLI generally maintained loading phase visual acuity gains up to Week 52 across quartile subgroups based on BCVA at screening Company remains on track to submit NDA based on SOL-1 alone, subject to planned formal discussions with the U.S. FDA, consistent with recent FDA public commentary BEDFORD, M

    4/13/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

    -- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome and highlights the importance of flexible, patient-centered treatment approaches Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE

    4/7/26 9:05:00 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Asana downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Asana from Overweight to Neutral and set a new price target of $7.00

    4/14/26 8:14:22 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Asana upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Asana from Underperform to Sector Perform and set a new price target of $7.00

    4/1/26 8:10:23 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    ACADIA Pharmaceuticals upgraded by BofA Securities with a new price target

    BofA Securities upgraded ACADIA Pharmaceuticals from Neutral to Buy and set a new price target of $29.00

    3/25/26 8:22:46 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Financials

    Live finance-specific insights

    View All

    NextNav Inc. Reports Fourth Quarter and Full Year 2025 Results and Operational Highlights

    NextNav confident FCC moving toward near-term NPRM NextNav Inc. (NASDAQ:NN) a leader in next generation positioning, navigation, and timing (PNT) and 3D geolocation, today reported its financial results and operational updates for the quarter ended and full year December 31, 2025. "We are confident the Federal Communications Commission (FCC) is moving toward a Notice of Proposed Rulemaking (NPRM) in the near term, supported by a robust and well‑developed record with a path to a Report and Order," said Mariam Sorond, CEO of NextNav. "FCC Chairman Brendan Carr's recent submission of a PNT rulemaking to the Office of Management and Budget represents an important milestone achieved in rapid

    3/17/26 4:05:00 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

    Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  "

    3/5/26 6:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana Announces Fourth Quarter and Fiscal Year 2026 Results

    Delivered Q4 revenue of $205.6 million, up 9% year over year Expanded Q4 GAAP operating margin by over 17 percentage points and non-GAAP operating margin by 10 percentage points Grew Q4 operating cash flow by 74% and adjusted free cash flow by 108% year over year Board authorized an additional $160M for share repurchases, bringing total authorization available to approximately $200M Asana, Inc. (NYSE:ASAN) (LTSE: ASAN), the system of action where humans and AI run work together, today reported financial results for its fourth quarter and fiscal year ended January 31, 2026. "FY26 was a year of meaningful progress as we advanced Asana into a multi-product platform and strengthened our pos

    3/2/26 4:05:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana to Appoint Aziz Megji to the Role of Chief Financial Officer

    Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), the system of action where humans and AI run work together, will promote Aziz Megji to the role of Chief Financial Officer (CFO), effective March 24, 2026. Megji will succeed Sonalee Parekh, who has served as Asana's CFO since 2024 and tendered her resignation effective March 23, 2026. Megji brings his experience from his Head of Financial Planning & Analysis role where he led the company's annual planning, budgeting, forecasting, and performance management processes, as well as overseeing the strategic finance, treasury, investor relations, corporate development, deal desk, and sales compensation functions. He partners closely with Asana's CEO and Boa

    3/2/26 4:06:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    NextNav Appoints Lisa Hook to Board of Directors

    NextNav Expands Board with Appointment of Seasoned Technology and National Security Leader NextNav Inc. (NASDAQ:NN), a leader in next-generation terrestrial Positioning, Navigation, and Timing (PNT) and 3D geolocation solutions, today announced the appointment of Lisa Hook to its Board of Directors, effective February 24, 2026. Ms. Hook will also serve as Lead Independent Director and has been appointed as a member of the Company's Technology and National Defense and Compensation and Human Capital Committees. "I am delighted to welcome Lisa to the NextNav Board of Directors," said Mariam Sorond, NextNav's Chief Executive Officer and Board Chair. "Her leadership in global information ser

    2/27/26 11:53:00 AM ET
    $NN
    Industrial Machinery/Components
    Industrials

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NextNav Inc.

    SC 13D/A - NEXTNAV INC. (0001865631) (Subject)

    12/6/24 6:03:25 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care